Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand

View More View Less
  • 1 Department of Neurological Surgery and The Virginia Neurological Institute, University of Virginia Health Sciences Center, Charlottesville, Virginia
Restricted access

Purchase Now

USD  $45.00

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
Print or Print + Online

✓ Tirilazad mesylate, a nonglucocorticoid 21-aminosteroid, has been shown in experimental models to reduce vasospasm following subarachnoid hemorrhage (SAH) and to reduce infarct size from focal cerebral ischemia. To test whether treatment with tirilazad would reduce ischemic symptoms from vasospasm and improve overall outcome in patients with ruptured aneurysms, a prospective randomized, double-blind, vehicle-controlled trial was conducted at 41 neurosurgical centers in Europe, Australia, and New Zealand. One thousand twenty-three patients were randomly assigned to receive 0.6, 2, or 6 mg/kg per day of intravenously administered tirilazad or a placebo containing the citrate vehicle. All patients were also treated with intravenously administered nimodipine. Patients receiving 6 mg/kg per day of tirilazad had reduced mortality (p = 0.01) and a greater frequency of good recovery on the Glasgow Outcome Scale 3 months after SAH (p = 0.01) than similar patients treated with vehicle. There was a reduction in symptomatic vasospasm in the group that received 6 mg/kg per day tirilazad; however, the difference was not statistically significant (p = 0.048). The benefits of treatment with tirilazad were predominantly shown in men rather than in women. There were no material differences between the outcomes in the groups treated with 0.6 and 2 mg/kg tirilazad per day and the group treated with vehicle. Tirilazad was well tolerated at all three dose levels.

These observations suggest that tirilazad mesylate, at a dosage of 6 mg/kg per day, is safe and improves overall outcome in patients (especially in men) who have experienced an aneurysmal SAH.

JNS + Pediatrics - 1 year subscription bundle (Individuals Only)

USD  $515.00

JNS + Pediatrics + Spine - 1 year subscription bundle (Individuals Only)

USD  $612.00
  • 1.

    Asano T, , Matsui T, & Takuwa Y: Lipid peroxidation, protein kinase C, and cerebral vasospasm. Crit Rev Neurosurg 1:361379, 1991 Asano T, Matsui T, Takuwa Y: Lipid peroxidation, protein kinase C, and cerebral vasospasm. Crit Rev Neurosurg 1:361–379, 1991

    • Search Google Scholar
    • Export Citation
  • 2.

    Drake CG: Report of World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg 68:985986, 1988 Drake CG: Report of World Federation of Neurological Surgeons Committee on a universal subarachnoid hemorrhage grading scale. J Neurosurg 68:985–986, 1988

    • Search Google Scholar
    • Export Citation
  • 3.

    Fleishaker JC, , Hulst-Pearson LK, & Peters GR: Effect of gender and menopausal status on the pharmacokinetics of tirilazad mesylate in healthy subjects. Am J Thera 2:553560, 1995 Fleishaker JC, Hulst-Pearson LK, Peters GR: Effect of gender and menopausal status on the pharmacokinetics of tirilazad mesylate in healthy subjects. Am J Thera 2:553–560, 1995

    • Search Google Scholar
    • Export Citation
  • 4.

    Fleishaker JC, , Peters GR, & Cathcart KS, et al: Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radial scavenger: I. Single-dose administration. J Clin Pharmacol 33:175181, 1993 Fleishaker JC, Peters GR, Cathcart KS, et al: Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radial scavenger: I. Single-dose administration. J Clin Pharmacol 33:175–181, 1993

    • Search Google Scholar
    • Export Citation
  • 5.

    Fleishaker JC, , Peters GR, & Cathcart KS, et al: Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. J Clin Pharmacol 33:182190, 1993 Fleishaker JC, Peters GR, Cathcart KS, et al: Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. J Clin Pharmacol 33:182–190, 1993

    • Search Google Scholar
    • Export Citation
  • 6.

    Haley EC Jr, , Kassell NF, & Alves WM, et al: Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage: a report of the Cooperative Aneurysm Study. J Neurosurg 82:786790, 1995 Haley EC Jr, Kassell NF, Alves WM, et al: Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage: a report of the Cooperative Aneurysm Study. J Neurosurg 82:786–790, 1995

    • Search Google Scholar
    • Export Citation
  • 7.

    Haley EC Jr, , Kassell NF, & Torner JC, et al: A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 78:537546, 1993 Haley EC Jr, Kassell NF, Torner JC, et al: A randomized controlled trial of high-dose intravenous nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 78:537–546, 1993

    • Search Google Scholar
    • Export Citation
  • 8.

    Haley EC Jr, , Kassell NF, & Torner JC, et al: A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 80:788796, 1994 Haley EC Jr, Kassell NF, Torner JC, et al: A randomized trial of two doses of nicardipine in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. J Neurosurg 80:788–796, 1994

    • Search Google Scholar
    • Export Citation
  • 9.

    Hall ED, , McCall JM, & Means ED: Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol 28:221268, 1994 Hall ED, McCall JM, Means ED: Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol 28:221–268, 1994

    • Search Google Scholar
    • Export Citation
  • 10.

    Hall ED, & Travis MA: Effects of the nonglucocorticoid 21-aminosteroid U74006F on acute cerebral hypoperfusion following experimental subarachnoid hemorrhage. Exp Neurol 102:244248, 1988 Hall ED, Travis MA: Effects of the nonglucocorticoid 21-aminosteroid U74006F on acute cerebral hypoperfusion following experimental subarachnoid hemorrhage. Exp Neurol 102:244–248, 1988

    • Search Google Scholar
    • Export Citation
  • 11.

    Jennett B, & Bond M: Assessment of outcome after severe brain damage. A practical scale. Lancet 1:480484, 1975 Jennett B, Bond M: Assessment of outcome after severe brain damage. A practical scale. Lancet 1:480–484, 1975

    • Search Google Scholar
    • Export Citation
  • 12.

    Jennett B, , Teasdale G, & Braakman R, et al: Prognosis of patients with severe head injury. Neurosurgery 4:283289, 1979 Jennett B, Teasdale G, Braakman R, et al: Prognosis of patients with severe head injury. Neurosurgery 4:283–289, 1979

    • Search Google Scholar
    • Export Citation
  • 13.

    Lyden P, , Brott T, & Tilley T, et al: Improved reliability of the NIH Stroke Scale using video training. Stroke 25:22202226, 1994 Lyden P, Brott T, Tilley T, et al: Improved reliability of the NIH Stroke Scale using video training. Stroke 25:2220–2226, 1994

    • Search Google Scholar
    • Export Citation
  • 14.

    Neter J, , Wasserman W, & Kutner N: Applied Linear Statistical Models, Regression, Analysis of Variance, and Experimental Designs. Boston: RD Irwin, 1990, pp 587589 Neter J, Wasserman W, Kutner N: Applied Linear Statistical Models, Regression, Analysis of Variance, and Experimental Designs. Boston: RD Irwin, 1990, pp 587–589

    • Search Google Scholar
    • Export Citation
  • 15.

    Park CK, & Hall ED: Dose—response analysis of the effect of 21-aminosteroid tirilazad mesylate (U-74006F) upon neurological outcome and ischemic brain damage in permanent focal cerebral ischemia. Brain Res 645:157163, 1994 Park CK, Hall ED: Dose—response analysis of the effect of 21-aminosteroid tirilazad mesylate (U-74006F) upon neurological outcome and ischemic brain damage in permanent focal cerebral ischemia. Brain Res 645:157–163, 1994

    • Search Google Scholar
    • Export Citation
  • 16.

    Schmidley JW: Free radicals in central nervous system ischemia. Stroke 21:10861090, 1990 Schmidley JW: Free radicals in central nervous system ischemia. Stroke 21:1086–1090, 1990

    • Search Google Scholar
    • Export Citation
  • 17.

    Steinke DE, , Weir BKA, & Findlay JM, et al: A trial of the 21-aminosteroid U74006F in a primate model of chronic cerebral vasospasm. Neurosurgery 24:179186, 1989 Steinke DE, Weir BKA, Findlay JM, et al: A trial of the 21-aminosteroid U74006F in a primate model of chronic cerebral vasospasm. Neurosurgery 24:179–186, 1989

    • Search Google Scholar
    • Export Citation
  • 18.

    Vollmer DG, , Kassell NF, & Hongo K, et al: Effect of the nonglucocorticoid 21-aminosteroid U74006F on experimental cerebral vasospasm. Surg Neurol 31:190194, 1989 Vollmer DG, Kassell NF, Hongo K, et al: Effect of the nonglucocorticoid 21-aminosteroid U74006F on experimental cerebral vasospasm. Surg Neurol 31:190–194, 1989

    • Search Google Scholar
    • Export Citation
  • 19.

    Wilson JT, , Bednar MM, & McAuliffe TL, et al: The effect of the 21-aminosteroid U74006F in a rabbit model of thromboembolic stroke. Neurosurgery 31:929934, 1992 Wilson JT, Bednar MM, McAuliffe TL, et al: The effect of the 21-aminosteroid U74006F in a rabbit model of thromboembolic stroke. Neurosurgery 31:929–934, 1992

    • Search Google Scholar
    • Export Citation
  • 20.

    World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964; amended October 1975, October 1983, and September 1989 World Medical Association Declaration of Helsinki: Recommendations Guiding Physicians in Biomedical Research Involving Human Subjects. Adopted by the 18th World Medical Assembly, Helsinki, Finland, June 1964; amended October 1975, October 1983, and September 1989

    • Search Google Scholar
    • Export Citation
  • 21.

    Xue D, , Slivka A, & Buchan AM: Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke 23:894899, 1992 Xue D, Slivka A, Buchan AM: Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Stroke 23:894–899, 1992

    • Search Google Scholar
    • Export Citation
  • 22.

    Zuccarello M, , Marsch JT, & Schmitt G, et al: Effect of the 21-aminosteroid U74006F on cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg 71:98104, 1989 Zuccarello M, Marsch JT, Schmitt G, et al: Effect of the 21-aminosteroid U74006F on cerebral vasospasm following subarachnoid hemorrhage. J Neurosurg 71:98–104, 1989

    • Search Google Scholar
    • Export Citation

Metrics

All Time Past Year Past 30 Days
Abstract Views 496 161 28
Full Text Views 288 17 0
PDF Downloads 98 12 0
EPUB Downloads 0 0 0